Beruflich Dokumente
Kultur Dokumente
Idntica evolucin de bacteriemias por SCN en neonatos tratados con cefalotina, oxacilina o vancomicina
Kredict et al, 1999
61%
57%
55% 15-40%
2%
3%
10%
CANDIDEMIA y CATTERES
Eppes et al, 1989: Mantener catter asociado con persistente candidemia (6/8 neonatos vs 2/13, p=0.02), ms complicaciones (3/8 vs 2/13) y muertes (2/8 vs 0/13) Dato, Dajani, 1990: Remocin temprana de catter (dentro de 1 da de HC+) asociada con menos complicaciones y letalidad vs remocin >2 das (0/6 vs 12/25, 5 muertes) Stamos, Rowley, 1995: 36% letalidad cuando catter no removido dentro de 3 das de HC+ (vs. no muertes)
Temp - R (n = 50)
Tarde - R (n = 54)
Candidemia 109(34 -322) 112(28-454) 0.34 Estancia (d) Das de 3 (1 - 14) 6 (1 - 24) 0.002 candidemia Das de 18 (5 - 60) 21 (5 - 51) 0.14 anfotericina Letalidad 1 (2%)
PEDIATRICS 2000; 106:e63
10 (19%)
0.008
J Chemother. 1999;11:504. Clin Infect Dis 2003;36:1221. J Clin Microbiol 2006; 44:760
TRATAMIENTO DE CANDIDIASIS
Anfotericina B (deoxicolato, formas lipdicas): duracin depende de severidad y tipo de infeccin:
Catter-asociada: 7-10 mg/kg (total) Diseminada: mnimo 20 mg/kg
Meningitis: 30 mg/kg Endocarditis: 40 mg/kg
2.5 1.0 x1000 nv (antes vs despus de cribado universal en Hospital Clnico, U. Catlica) Prevencin y control de Infecciones nosocomiales (lavado de manos) Prevencin de infeccin de catteres vasculares Profilaxis con fluconazol en prematuros Probiticos para evitar enterocolitis
Veeeeeeeee
TERAPIA ADYUVANTE
EXANGUINO-TRANSFUSIN TRANSFUSIN DE GRANULOCITOS INMUNOGLOBULINA ENDOVENOSA
Cochrane Library (issue 4, 2001)
NO NO
Sepsis clnica (n=318), RR 0.63 (0.4-1.0) Sepsis probada (n=262), RR 0.55 (0.3-0.98)
FINDINGS: 477 patients were enrolled; 237 received placebo, and 240 DrotAA. Our results showed no significant difference between groups in CTCOFR score (p=0.72) or in 28-day mortality (placebo 17.5%; DrotAA, 17.2%; p=0.93). Although there was no difference in overall serious bleeding events during the 28-day study period (placebo 6.8%; DrotAA 6.7%; p=0.97), there were numerically more instances of CNS bleeding in the DrotAA group (11 [4.6%], vs 5 [2.1%] in placebo, p=0.13), particularly in children younger than 60 days. For CTCOFR score days 1-14, correlation coefficient was -0.016 (95% CI -0.106 to 0.74); relative risk for 28-day mortality was 1.06 (95% CI 0.66 to 1.46) for DrotAA compared with placebo. INTERPRETATION: Although we did not record any efficacy of DrotAA in children with severe sepsis, serious bleeding events were similar between groups and the overall safety profile acceptable, except in children younger than 60 days. However, we gained important insights into clinical and laboratory characteristics of childhood severe sepsis, and have identified issues that need to be addressed in future trials in critically ill children.
En
PC n A
i os